20.74
-0.68 (-3.17%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Specialty Chemicals (US) | Bearish | Bearish |
| Specialty Chemicals (Global) | Bearish | Bearish | |
| Stock | Avantor, Inc. | Bullish | - |
Stockmoo Score
|
Avantor Inc is involved in providing products and services to biopharma, healthcare, education and government, and advanced technologies and applied materials industries. The company's offerings include materials and consumables, equipment and instrumentation and services and specialty procurement. Its brand profile consists of NuSil, RANKEM, POCH, BeneSphera, and Macron Fine Chemicals among others. The firm operates in three geographical segments namely Americas, Europe, and AMEA. It generates a majority of its revenue from the Americas. |
|
| Sector | Basic Materials |
| Industry | Specialty Chemicals |
| Investment Style | Mid Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| New Mountain Capital, L.L.C. | 31 Mar 2024 | 14,000,000 |
| Artemis Investment Management Llp | 30 Jun 2024 | 8,068,480 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 31.00 (RBC Capital, 49.47%) | Buy |
| Median | 26.00 (25.36%) | |
| Low | 23.00 (Citigroup, 10.90%) | Hold |
| Average | 26.40 (27.29%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 21.52 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 15 Jul 2024 | 31.00 (49.47%) | Buy | 20.82 |
| Citigroup | 10 Jul 2024 | 23.00 (10.90%) | Hold | 20.90 |
| Evercore ISI Group | 02 Jul 2024 | 27.00 (30.18%) | Buy | 20.58 |
| Barclays | 28 Jun 2024 | 25.00 (20.54%) | Buy | 21.20 |
| Baird | 29 Apr 2024 | 26.00 (25.36%) | Buy | 24.08 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Jul 2024 | Announcement | Avantor® Reports Second Quarter 2024 Results |
| 23 Jul 2024 | Announcement | Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600 |
| 01 Jul 2024 | Announcement | Avantor® Announces New J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease |
| 28 Jun 2024 | Announcement | Avantor® to Host Second Quarter 2024 Earnings Call on Friday, July 26, 2024 |
| 21 Jun 2024 | Announcement | Avantor® Appoints Corey Walker as President of Laboratory Solutions |
| 18 Jun 2024 | Announcement | Avantor® Releases 2024 Science for Goodness Sustainability Report |
| 29 May 2024 | Announcement | Avantor® to Participate in Goldman Sachs Global Healthcare Conference |
| 21 May 2024 | Announcement | Avantor® to Participate in Bernstein's 40th Annual Strategic Decisions Conference |
| 03 May 2024 | Announcement | Avantor® to Participate in BofA Securities 2024 Health Care Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |